PHASE-II TRIAL OF ECHINOMYCIN FOR THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY

Authors
MARSHALL ME WOLF MK CRAWFORD ED TAYLOR S BLUMENSTEIN B FLANIGAN R MEYERS FJ HYNES HE BARLOGIE B EISENBERGER M
Citation
Me. Marshall et al., PHASE-II TRIAL OF ECHINOMYCIN FOR THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Investigational new drugs, 11(2-3), 1993, pp. 207-209
Citations number
5
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Investigational new drugs → ACNP
ISSN journal
01676997
Volume
11
Issue
2-3
Year of publication
1993
Pages
207 - 209
Database
ISI
SICI code
0167-6997(1993)11:2-3<207:PTOEFT>2.0.ZU;2-3
Abstract
Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase 11 trial of Echinomycin. Treatment consisted o f Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 eva luable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0-11%). Eighteen patients (38%) experienced toxicity of grade 3 or wor se. The most common toxicities were nausea and vomiting. The results o f this study indicate that Echinomycin is not sufficiently active to w arrant further trials for the treatment of renal cell carcinoma.